NHPAP trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NHPAP achieves its forward estimates and maintains a stable P/E multiple of 130.8x. This scenario reflects the blended consensus of multiple Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 29, 2026, National Healthcare Properties, Inc. (NHPAP) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $655M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, NHPAP trades at a trailing P/E of -9.2x and forward P/E of 130.8x. Analysts expect EPS to grow +108.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NHINational Health Investors, Inc. | $3.8B | $77.55 | $82.83 | +6.8% | Hold | 21.8x | 18 |
OHIOmega Healthcare Investors, Inc. | $14.3B | $48.06 | $50.43 | +4.9% | Hold | 24.2x | 28 |
SBRASabra Health Care REIT, Inc. | $4.9B | $19.54 | $21.00 | +7.5% | Hold | 29.0x | 29 |
LTCLTC Properties, Inc. | $2.0B | $38.46 | $36.00 | -6.4% | Hold | 20.5x | 22 |
CTRECareTrust REIT, Inc. | $9.6B | $40.83 | $44.25 | +8.4% | Buy | 27.4x | 19 |
GMREGlobal Medical REIT Inc. | $94M | $35.74 | $40.00 | +11.9% | Buy | 595.7x | 22 |
VTRVentas, Inc. | $42.3B | $89.05 | $95.86 | +7.6% | Buy | 142.7x | 32 |
WELLWelltower Inc. | $159.2B | $227.21 | $237.80 | +4.7% | Buy | 78.4x | 35 |
HRHealthcare Realty Trust Incorporated | $7.2B | $20.50 | $21.83 | +6.5% | Hold | — | 30 |
DOCHealthpeak Properties, Inc. | $15.0B | $21.55 | $19.71 | -8.5% | Buy | 66.7x | 41 |
Quick answers to the most common questions about buying NHPAP stock.
The consensus price target for NHPAP is $N/A, close to the current price of $23.12 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
NHPAP has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
At a forward P/E of 130.8432x, NHPAP trades at a premium valuation. The consensus price target of $N/A (N/A% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $N/A for NHPAP, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
NHPAP is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NHPAP stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
NHPAP trades at a forward P/E ratio of 130.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
NHPAP appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NHPAP analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.